anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An eight-week feeding trial was designed to assess which component of commensal Bacillus siamensis LF4 can mitigate SBM-induced enteritis and microbiota dysbiosis in spotted seabass (Lateolabrax maculatus) based on TLRs-MAPKs/NF-кB signaling pathways. Fish continuously fed low SBM (containing 16 % SBM) and high SBM (containing 40 % SBM) diets were used as positive (FM group) and negative (SBM group) control, respectively. After feeding high SBM diet for 28 days, fish were supplemented with B. siamensis LF4-derived whole cell wall (CW), cell wall protein (CWP), lipoteichoic acid (LTA) or peptidoglycan (PGN) until 56 days. The results showed that a high inclusion of SBM in the diet caused enteritis, characterized with significantly (P < 0.05) decreased muscular thickness, villus height, villus width, atrophied and loosely arranged microvillus. Moreover, high SBM inclusion induced an up-regulation of pro-inflammatory cytokines and a down-regulation of occludin, E-cadherin, anti-inflammatory cytokines, apoptosis related genes and antimicrobial peptides. However, dietary supplementation with CW, LTA, and PGN of B. siamensis LF4 could effectively alleviate enteritis caused by a high level of dietary SBM. Additionally, CWP and PGN administration increased beneficial Cetobacterium and decreased pathogenic Plesiomonas and Brevinema, while dietary LTA decreased Plesiomonas and Brevinema, suggesting that CWP, LTA and PGN positively modulated intestinal microbiota in spotted seabass. Furthermore, CW, LTA, and PGN application significantly stimulated TLR2, TLR5 and MyD88 expressions, and inhibited the downstream p38 and NF-κB signaling. Taken together, these results suggest that LTA and PGN from B. siamensis LF4 could alleviate soybean meal-induced enteritis and microbiota dysbiosis in L. maculatus, and p38 MAPK/NF-κB pathways might be involved in those processes.
Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
The use of a chlorogenic acid in active agents for slimming in cosmetics is new. An independent claim is included for composition comprising caffeine and at least one chlorogenic acid, where the ratio of between the concentrations of chlorogenic acid and caffeine is 1:1-1:500 (preferably 1:2-1:100). ACTIVITY : None given. MECHANISM OF ACTION : Lipogenesis inhibitor; Lipolysis activator. The ability of chlorogenic acid to inhibit phosphodiesterase (activation of lipolysis) was tested. The results showed that the chlorogenic acid effectively inhibited the phosphodiesterase by exhibiting an IC 50value of 0.12%, which was less when compared to that of caffeine (i.e. 1%).
Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
INTRODUCTION: The PROGRESER study is a multicentre, prospective, observational, 3-year follow-up study of a cohort of patients with stage 3 chronic kidney disease (CKD) from different nephrology departments of hospitals in the Spanish healthcare system. The primary study objective was to analyse risk factors for CKD progression, identifying possible differences between patients with and without diabetes mellitus (DM). The secondary objective was to analyse if the cardiovascular risk factors were also associated with CKD progression.
PATIENTS AND METHODS: A total of 462 patients (342 men and 120 women; mean age 66.5 ± 11.5 years) were recruited from 25 participating sites in Spain. Clinical, epidemilogical and analytical data were recorder in an electronic registrer each six months. Biological samples were obtained and frozen for a biobank record at baseline and at 18 and 36 months.
RESULTS: The initial mean glomerular filtration rate estimated by MDRD and after that reestimated by CKD-EPI was 43.9 ± 7.9 mL/min/1.73 m2; and 29 ± 6,8 mL/min/1,73 m2 at 3 years. 27.3% of patients had microalbuminuria and 22.5% had macroalbuminuria. Two-thirds of the patients (66.2%) presented renal damage progression according to the study criteria (decrease of more than 15% in eGFR over the baseline value). 38.7% presented a reduction in eGFR ≥ 30%; 20.3% had a reduction in eGFR ≥40%; 10.4% had a reduction ≥50% and 6.9% had a reduction ≥57%. Of the 199 diabetics, 134 (67.3%) suffered renal damage progression. Of the 263 non-diabetics, 172 (65.3%) presented progression (p = 0.456). 27.3% of patients had microalbuminuria and 22.5% proteinuria. The study found that CKD progression to a higher stage was not greater in diabetic compared to non-diabetic patients. Multivariate analysis revealed that the presence of arterial hypertension bordered on significance as a progression factor in non-diabetic patients (p = 0.07), and that, in diabetic patients, lower calcium levels and elevated intact parathyroid hormone levels at baseline were associated with progression.
CONCLUSION: in our study we have not found new factors for progression of renal damage, different from the yet well known traditional factors. DM "per se" was not a differential factor for progression in relation with non DM patients. Progression of renal damage in patients with CKD-3 KDOQI may be interpreted in a multifactorial context. The search for new biomarkers, different from traditional ones, is necessary to establish new therapeutic strategies to prevent the progression of CKD.
FIELD: medicine. SUBSTANCE: described are β(1→6) glucosamine disaccharides of formula I:   wherein   are as defined in claims. Also described are method of preparing said glucosamine disaccharides, and pharmaceutical composition comprising said disaccharides as active ingredient. The claimed compounds are useful in medical treatment or prophylaxis as immune-modulating, antitumor agents and vaccine components. EFFECT: improved properties of the title compounds. 34 cl, 19 dwg, 7 ex, 10 tbl
The immunological basis for cardiac deaths remote from potential triggering viral infection, including SARS-CoV-2 infection, remains enigmatic. Cardiac surface inflammation, including the pericardium, epicardium and superficial myocardium with associated coronary artery vasculitis in infant Kawasaki Disease (KD) and multisystem inflammatory syndrome in children (MIS-C) is well recognised. In this perspective, we review the evidence pointing towards prominent post-viral infection related epicardial inflammation in older subjects, resulting in atherosclerotic plaque destabilisation with seemingly unrelated myocardial infarction that may be temporally distant from the actual infectious triggers. Cardiac surface inflammation in the relatively immune cell rich tissues in the territory though where the coronary arteries traverse is common in the adult post-COVD pneumonic phase and is also well described after vaccination including pre-COVID era vaccinations. Immunologically, the pericardium/epicardium tissue was known to be critical for coronary artery territory atherosclerotic disease prior to the COVID-19 era and may be linked to the involvement of the coronary artery vasa vasorum that physiologically oxygenates the coronary artery walls. We highlight how viral infection or vaccination-associated diffuse epicardial tissue inflammation adjacent to the coronary artery vasa vasorum territory represents a critical unifying concept for seemingly unrelated fatal coronary artery atherosclerotic disease, that could occur soon after or remote from infection or vaccination in adults. Mechanistically, such epicardial inflammation impacting coronary artery vasa vasorum immunity acts as gateways towards the slow destabilisation of pre-existing atherosclerotic plaques, with resultant myocardial infarction and other cardiac pathology. This model offers immunologists and academic cardiologists an immunopathological roadmap between innocuous viral infections or vaccinations and seemingly temporally remote "unrelated" atherosclerotic disease with excess cardiac deaths.
Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with 5 minutes and increasing to 20 minutes over the course of the 6-week intervention - as is standard with the Mindfulness Awareness Practices (MAPs) course - with practice prior to bedtime. An intervention training manual is the cornerstone of standardized delivery of MAP-I. Participants are also provided with a book on mindfulness (Fully Present: The Science, Art, and Practice of Mindfulness, authored by the Mindfulness Awareness Research Center (MARC) leader and MAP-I instructor Diana Winston) as well as access to the University of California Los Angeles (UCLA) Mindful App courtesy of the MARC at UCLA (via personal iPhone or study-administered tablets per patient preference), which contains pre-recorded guided meditations for use in daily practice.
The purpose of this study is to evaluate the effect of prebiotic or synbiotic supplementation on inflammatory response and indicators of nutritional status in patients with morbid obesity. Adult individuals of both sexes with morbid obesity (body mass index ≥ 40 kg/m²) will be invited to participate in this randomized, placebo-controlled, triple-blind study. The participants will be divided into three groups: G1 - control group (placebo), G2 - prebiotic group and G3 - synbiotic group. The study will consist of four experimental time points: M0 - baseline and start of supplementation; M1 - after fifteen days of the first outpatient visit and fifteen days after the start of supplementation with prebiotic, synbiotic or placebo; M2 - after thirty days from the first outpatient visit and end of supplementation with prebiotic, synbiotic and placebo; and M3 - time after sixty days from the first outpatient visit. At all time points the inflammatory response will be assessed by determination of plasma cytokines (IL-1, IL-6, IL-10, TNF) and acute phase proteins (c-reactive protein and albumin), besides the evaluation of laboratory and anthropometric indicators of nutritional status. The primary endpoint will be the reduction in concentrations of inflammatory markers (cytokines and acute phase proteins).

Investigators expect to contribute with new information in this field of knowledge, which may facilitate the clinical application of these results.
This group of patients will instructed to swallow their saliva twice 10 minutes before induction of anesthesia. Other anesthetic care will follow routine protocol of the hospital.
The treatment phase foresees 5 cycles of Dinutuximab Beta. Dinutuximab Beta administration is restricted to hospital-use only and must be administered under the supervision of a physician experienced in the use of oncological therapies. It must be administered by a healthcare professional prepared to manage severe allergic reactions including anaphylaxis in an environment where full resuscitation services are immediately available. The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.
Atopic dermatitis (AD) is a chronic inflammatory skin condition with a high prevalence worldwide. AD pathogenesis is complex and consists of immune system dysregulation and impaired skin barrier, influenced by genetic and environmental factors. The purpose of the review is to show the complex interplay between atopic dermatitis and the microbiota. Human microbiota plays an important role in AD pathogenesis and the course of the disease. Dysbiosis is an important factor contributing to the development of atopic diseases, including atopic dermatitis. The gut microbiota can influence the composition of the skin microbiota, strengthening the skin barrier and regulating the immune response via the involvement of bacterial metabolites, particularly short-chain fatty acids, in signaling pathways of the gut-skin axis. AD can be modulated by antibiotic intake, dietary adjustments, hygiene, and living conditions. One of the promising strategies for modulating the course of AD is probiotics. This review offers a summary of how the microbiota influences the development and treatment of AD, highlighting aspects that warrant additional investigation.
FIELD: medicine, stomatology. SUBSTANCE: invention proposes an agent for treatment and prophylaxis of mouth cavity sicknesses that has a biologically active substance - coniferous sodium chlorophyllin, film-forming agent - gelatin or agar-agar and water and components are taken at the definite quantitative ratio. An agent can be made as plates of random form. An agent shows the positive effect on trophism and mouth cavity mucosa and paradontium blood supply. EFFECT: enhanced positive effect of an agent. 2 cl, 1 tbl
1,267,618. Antiseptic compositions. STAFFORD-MILLER Ltd. 25 Aug., 1970 [28 Aug., 1969], No. 40801/70. Headings A5B and A5E. An antiseptic composition, which is particularly useful for treating the mucous membranes of the oral cavity, comprises urea peroxide (NH 2 CONH 2 H 2 O 2 ), glycerol and a carboxypolymethylene polymer or metal or amine salt thereof, which polymer is soluble in glycerol and increases the viscosity of the glycerol. The carboxypolymethylene polymers may comprise interpolymers of a major proportion of one or more alpha, beta-olefinically unsaturated carboxylic acids and a minor proportion of a polyalkenyl polyether of a polyol, e.g. a polyallyl ether of a polyhydric alcohol containing at least three hydroxyl groups. Suitable polyallyl polyethers of polyols include allyl ethers having an average of at least two allyl groups per molecule and which are ethers of sucrose, sorbitol, glucose, mannitol, pentaerythritol, 1,2,3-butanetriol and xylitol. Additional monomers which may be included in the polymer are vinyl acetate, acrylamide and vinyl pyrrolidone. The carboxy polymethylene polymers are included in amount sufficient to provide a gel having a viscosity of at least 1000 centipoises at 20C. The glycerol may be anhydrous or up to 10% of the composition may be water, in which case it is desirable to incorporate a peroxide stabilising agent, e.g. phenocetin, acetanilide, 8-hydroxyquinoline, stannous salts, ethylenediaminetetracetic acid derivatives. Other glycerol-soluble components may be added, e.g. therapeutically acceptable dyes and/or flavouring agents.
FIELD: medicine, hysteroscopy. SUBSTANCE: the innovation is represented by LH-RH-antagonist, Cetrorelix, in particular. It is indicated to be used before hysteroscopy and/or preparation for operation, or in case of single usage ranged 0.1-2 mg/kg, or for preparation to operation at multiple dosage ranged 0.01-0.5 mg/kg, preferably distributed for 1-14 d. The suggested product could be used at hysteroscopy at combination with subsequent treatment of painful uterine states, for example, myoma and endometrial hyperplasia. The method enables to improve results of hysteroscopy and shorten the time necessary for preparation to operation. EFFECT: higher efficiency of diagnostics. 4 cl, 3 dwg, 1 tbl
PURPOSE:To obtain a skin and a hair cosmetics and a cosmetic in the mouth containing an oil of a bush Melaleuca alternifolia which is an essential oil extracted from the Melaleuca alternifolia growing in a marshy district in Australia. CONSTITUTION:The cosmetic, especially the skin cosmetic, hair cosmetic and cosmetic in the mouth contains an oil of a bush Melaleuca alternifolia which is an essential oil extracted from a leaf, a bark or the wood of the Melaleuca alternifolia growing in a marshy district in Australia by steam distillation or with a hydrophobic organic solvent. The oil of the Melaleuca alternifolia has action on the absorption of ultraviolet rays harmful to the human body and the persistence of effects thereof is high. Furthermore, the safety for the skin is high and this oil manifests proteolytic and deodorant actions. When this cosmetic is applied to the skin, it is effective in preventing erythema of the skin produced by harmful ultraviolet rays or conditioning the skin. When the cosmetic is applied to the hair, it is effective in protecting damaged hair. This cosmetic is further effectively used as a preventing agent for the halitosis.
Dental fear is among the most common individual phobias, and has devastating effects on oral and physical health, as well as emotional well-being. The behavioral avoidance associated with dental fear leads to neglect of prophylactic care, more dental emergencies, increased pain and suffering for individuals, and greater financial burdens, both for patients and society at large. Treatment remains inaccessible to the vast majority of fearful patients. Extremely efficacious brief evidence-based interventions for dental fear have not been administered outside of the specialty clinics in which they were developed. This is despite the ubiquitous nature of dental fear and its well-document impact on public health. Further, none of these existing treatment models can be easily incorporating into dental practices (due to issues of logistics, credentialed providers, time, financial costs, and disruptions of workflow).

Research is needed on how to disseminate and implement such treatment in a way that recognizes the barriers to accessing and entering treatment for dental fear. The investigators propose to pilot test, for feasibility and acceptability, Dental FearLess, a brief, free, self-directed, computerized intervention for moderate-to-severe dental fear that can be implemented in the waiting room of dental offices. Patients reporting moderate-to-severe dental fear after completing Dental FearLess will be offered a follow-up 1-hour session that covers the same content in person. Clearly, the challenge at present is not how to treat dental fear to reduce the financial and human suffering burden to public health, but how to disseminate and implement Evidence Based Interventions (EBIs) for dental fear in a way that recognizes the rewards and barriers in the U.S. healthcare system.

Stepped-care interventions have demonstrated efficacy for other behavioral and emotional problems. The investigators aim to test whether such interventions are feasible and acceptable, for both dentists and patients, for dental fear. If the pilot evaluation shows promise, it can be tested in larger studies and, if effective, be more widely implemented in the normal course of dental practice. This could improve uptake and, ultimately, patient outcomes compared with existing psychosocial interventions for dental fear.
This study will be conducted in three segments: Part A, Part B and Part C. Parts A and B are 12 weeks of treatment followed by 4 weeks of evaluation. In part A patients will dose-escalate up to three dose levels of PCI-27483 administered as subcutaneous (SC) injections twice-daily (BID). Part B to start once 4th patient completes 90 of 112 doses in 8 weeks. In part B patients are randomized to PCI-27483 and gemcitabine (active arm) OR gemcitabine only (control arm). PCI-27483 doses in both Part A and B will be administered in combination with a standard regimen of gemcitabine. Patients with a tumor response or stable disease at 12 weeks will have the opportunity to continue PCI-27483 treatment until disease progression or the Investigator considers the study treatment to be no longer tolerable. Treatment with gemcitabine in either the active or control arm may continue until a standard course of gemcitabine therapy has been completed. Patients will complete Part A or Part B after 16 weeks on study regardless of treatment duration. Evaluable patients will roll over into part C and be followed for 12 months from enrollment (first dose).
The coexistence of an arteriovenous fistula (AVF) and neuronal migration abnormalities is a rare phenomenon. The underlying pathophysiology responsible for these anomalies remains elusive. Neuronal architectural irregularities arise from complex neuronal formation, migration and organisation dysfunctions. Isolated cases of these associations are rarely described in the literature. Here, we present an unusual case involving the coexistence of a pial AVF and a pachygyria-polymicrogyria complex in an early childhood boy. We have provided a detailed description of the neuroimaging characteristics and the therapeutic embolisation in this case, along with follow-up. Additionally, we conduct a comprehensive review of potential hypotheses about the association, referencing prior case reports. The presence of an aberrant blood supply or deviant venous drainage from the developing cortex may contribute to a variety of neuronal migration anomalies.
A beta-amyloid positive conversion target prediction device according to one embodiment of the present invention may include: a patient information analysis unit; a genotype analysis unit; a standardized update value ratio (SUVR) analysis unit; and an artificial intelligence (AI) model. The patient information analysis unit may provide first input information by differentiating age and gender of a beta-amyloid negative patient based on basic information about a patient. The genotype analysis unit may provide second input information for determining whether a patient has an apoprotein genotype. The SUVR analysis unit may provide an SUVR calculated from amyloid positron emission tomography (PET) test results of the patient as third input information. The AI model may provide a prediction result for predicting a beta-amyloid positive conversion status of a beta-amyloid negative patient based on at least one among the first input information, the second input information, and the third input information. According to the present invention, the beta-amyloid positive conversion target prediction device may provide a prediction result for predicting a beta-amyloid positive conversion status of a negative patient using an artificial intelligence mode that is trained in advance based on at least one among first input information corresponding to age and gender of the beta-amyloid negative patient, second input information regarding whether the patient has an apoprotein genotype, and third input information corresponding to the SUVR. Accordingly, the beta-amyloid positive conversion target prediction device can predict patients who may develop Alzheimer's disease in advance.